EIF2AK3 and neoplasm: Persistent activation of PERK in tumor antigen-specific T cells was associated with compromised mitochondrial function; consistently, inhibiting PERK activity in T cells led to a reduction in mitochondrial ROS, resulting in enhanced anti-tumor immunity [188].